title: The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever.
abstract: BACKGROUND
  Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by self-limited recurrent attacks of fever and serositis. Patients may develop renal amyloidosis. Colchicine prevents attacks and renal amyloidosis. Five to 10 % of the patients with FMF are resistant or intolerant to colchicine.
  
  
  METHODS
  Herein, we reported our experience with clinical-laboratory features and treatment responses of a pediatric FMF patient with amyloidosis treated with canakinumab. We observed a significant decrease in proteinuria and increase growth in the patient.
  
  
  RESULTS
  The most serious complication of FMF is the development of AA type amyloidosis which is characterized by proteinuria. Colchicine is the prototype drug that decreases production of amyloidogenic precursor protein. Occasionally, colchicine inadequate patient is observed, as in our case. Canakinumab is a human anti-IL-1β monoclonal antibody. Previously, canakinumab efficacy were shown in a limited number of studies.
  
  
  CONCLUSIONS
  Our data, though limited to only one patient, emphasize that therapeutic intervention with canakinumab seems to be improve kidney function in colchicine-resistant FMF with renal amyloidosis.
authors: Department of Pediatric Rheumatology, Ege University Faculty of Medicine, Izmir, Turkey. betulsozeri@yahoo.com.
authors: Betul
authors: B
authors: Sozeri
authors: Dr. Behcet Uz Children Diseases Teaching and Research Hospital Pediatric Immunology and Rheumatology, Izmir, Turkey.
authors: Nesrin
authors: N
authors: Gulez
authors: Dr. Behcet Uz Children Diseases Teaching and Research Hospital Pathology, Izmir, Turkey.
authors: Malik
authors: M
authors: Ergin
authors: Dr. Behcet Uz Children Diseases Teaching and Research Hospital Pediatric Nephrology, Izmir, Turkey.
authors: Erkin
authors: E
authors: Serdaroglu
keywords: Amyloidosis; Canakinumab; Child; Familial Mediterranean fever